Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 6Wilms Tumor 3Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Sarcoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Kidney Neoplasms 2Glioblastoma 2Central Nervous System Neoplasms 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Squamous Intraepithelial Lesions 1Rectal Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Melanoma 1Gliosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cognition Disorders 1Brain Neoplasms 1Astrocytoma 1Anus Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Cognition Disorders × DNA Methylation × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡